
Opinion|Videos|November 22, 2024
Case 2: Diabetic Macular Edema With Severe Vision Loss
In the second case, Scott D. Walter, MD, MSc, FASRS presents a patient case of diabetic macular edema (DME) where each eye was treated with a different agent. Walter presents optical coherence tomograph (OTC) outcome similarities and differences in key criteria, such as neovascularization, micro aneurism leakage, and macular leakage.
Advertisement
Episodes in this series

Advertisement
Related to this article

In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.

Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.

What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
2
Duravyu misses wet AMD end point again as EyePoint pivots to DME
3
The Retina TL;DR with Dr. Weng: Thriving in fellowship with Amer Alsoudi, MD, and Monia Reding, MD
4
A vascular link: erectile dysfunction may signal glaucoma risk in men
5


